Myocardial perfusion scintigraphy for the diagnosis and management of angina and
KEYWORDS: spect, cad, patients, committee, studies, secg, cardiac, cost, myocardial, diagnostic, clinical, strategy, assessment, nhs, considered

was prepared by the Health Services Research Unit in collaboration with the Health Economics Research Unit, the Department of Public Health, Institute of Applied Health Sciences, and the Cardiology Research Group, University of Aberdeen, and the Department of Bio-Medical Physics and Bio-Engineering, Grampian University Hospitals NHS Trust. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction Graham Mowatt, Luke Vale, Miriam Brazzelli, Rodolfo Hernandez, Alison Murray, Neil Scott, Cynthia Fraser, Lynda McKenzie, Howard Gemmell, Graham Hillis, and Malcolm Metcalfe, May 2003. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, assessment report and the Appraisal Consultation Document (ACD). Consultee organisations are provided with the opportunity to appeal against the Final Appraisal Determination. Companies or sponsors: • Amersham Health • Ashby GB Ltd • Bartec Medical Systems (UK) Ltd • Bristol-Myers Squibb • GE Medical Systems • Philips Medical Systems • Siemens • Tyco Healthcare UK Ltd Professional or specialist, and patient or carer groups: • Action Heart • Association of British Health-Care Industries • British Cardiac Patients Association • British Cardiac
